Post-marketing, prospective and non-randomized trial regarding to daclatasvir and asunaprevir combination therapy for chronic liver disease with genotype 1 hepatitis C virus
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Asunaprevir/daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 05 Jul 2017 Planned number of patients changed from 200 to 230.
- 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2017 New trial record